The following table presents the compensation awarded to or earned by each of our NEOs for the years ended December 31, 2023, 2022 and 2021.
| | | | | | | | | | | | | | | | | |
|---|
| Name and Principal Position | | Year | | Salary($) | | Bonus | | Stock Awards($)(1) | | Option Awards($)(1) | | Non-Equity Incentive Plan Compensation($)(2) | | All Other Compensation($) | | Total($) |
|---|
| Douglas Manion(4) | | 2023 | | 600,000 | | - | | 1,832,760 | | 4,513,721 | | 198,000 | | 13,200 | (3) | 7,157,681 |
|---|
| Former President and Chief Executive Officer | | 2022 | | 204,167 | | - | | 848,526 | | 2,067,346 | | 82,159 | | - | | 3,202,198 |
|---|
| Kevin Balthaser(5) | | 2023 | | 444,000 | | - | | 509,100 | | 1,253,812 | | 124,320 | | 13,200 | (3) | 2,344,432 |
|---|
| Chief Financial Officer | | | | | | | | | | | | | | | | |
|---|
| Joseph Monahan | | 2023 | | 374,400 | | - | | 509,100 | | 1,253,812 | | 104,832 | | 13,200 | (3) | 2,255,344 |
|---|
| Chief Scientific Officer | | 2022 | | 420,000 | | - | | 652,878 | | 1,570,083 | | 168,000 | | 12,021 | (3) | 2,822,982 |
|---|
| | | 2021 | | 350,000 | | - | | 4,812,000 | | - | | 154,700 | | 10,605 | (3) | 5,327,305 |
|---|
| Gail Cawkwell(6) | | 2023 | | 490,000 | | - | | 509,100 | | 1,253,812 | | 137,200 | | 13,200 | (3) | 2,403,312 |
|---|
| Former Chief Medical Officer | | 2022 | | 247,273 | | 25,000 | (7) | 896,400 | | 2,030,642 | | 98,893 | | 800 | (3) | 3,299,008 |
|---|
| James Loerop(8) | | 2023 | | 435,000 | | - | | 509,100 | | 1,253,812 | | 121,800 | | 13,200 | (3) | 2,332,912 |
|---|
| Chief Business Officer | | | | | | | | | | | | | | | | |
|---|
| (1) | The amounts reflect the full grant date fair value for RSU and stock option awards granted during the indicated year. The grant date fair value was computed in accordance with ASC Topic 718, Compensation—Stock Compensation. The assumptions we used in valuing stock options and restricted stock unit awards are described in Note 9 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. |
| (2) | The amounts reflect the portion of each officer’s target annual bonus paid based on the achievement of our corporate and individual goals, as applicable, which for 2023 are discussed further above under “Compensation Program and Decisions—Annual Bonus (Non-Equity Incentive Plan Compensation).” |
| (3) | The amount consists of company matching contributions to the executive's 401(k) plan account. |
| (4) | Dr. Manion’s employment with us began in August 2022 and ended in January 2024. |
| (5) | Mr. Balthaser was not one of our executive officers during the years ended December 31, 2022 and 2021 and, accordingly, only his compensation for the year ended December 31, 2023 is included in the Summary Compensation Table in accordance with SEC rules. |
| (6) | Dr. Cawkwell’s employment with us began in June 2022 and ended in January 2024. |
| (7) | The amount reflects Dr. Cawkwell’s signing bonus. |
| (8) | Mr. Loerop began his employment with us in January 2022 and was not an NEO for the year ended December 31, 2022. Accordingly, only his compensation for the year ended December 31, 2023 is included in the Summary Compensation Table in accordance with SEC rules. |
